SCHEMBL7148874

SCHEMBL7148874

CC(C)(C)OC(=O)[C@@H]1C[C@H](OS(C)(=O)=O)CN1S(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MME P08473 2/20 0.42
ACE P12821 2/20 0.42
ECE1 P42892 2/20 0.42
CASP3 P42574 1/20 0.41
LMNA P02545 3/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
ACACB O00763 1/20 0.41
AKR1C3 P42330 3/20 0.40
AKR1C1 Q04828 1/20 0.40
MCL1 Q07820 1/20 0.39
CCR4 P51679 2/20 0.39
MCOLN3 Q8TDD5 1/20 0.38
HPGD P15428 1/20 0.38
MMP9 P14780 1/20 0.38
KMT2A Q03164 2/20 0.38
PKM P14618 2/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7141875 1.00 MME (0.42) MMEACEECE1CASP3LMNA
SCHEMBL7142526 0.89 MME (0.46) MMEACEECE1LMNAALDH1A1
SCHEMBL7152576 0.89 MME (0.46) MMEACEECE1LMNAALDH1A1
SCHEMBL7143312 0.88 ALDH1A1 (0.48) MMEACEECE1CASP3LMNA
SCHEMBL7148996 0.88 ALDH1A1 (0.48) MMEACEECE1CASP3LMNA
SCHEMBL6860718 0.86 AKR1C3 (0.48) MMEACEECE1LMNAALDH1A1
SCHEMBL7145366 0.82 MME (0.42) MMEACEECE1CASP3LMNA
SCHEMBL7137614 0.82 MME (0.42) MMEACEECE1CASP3LMNA
SCHEMBL7137755 0.77 MME (0.54) MMEACEECE1LMNAALDH1A1
SCHEMBL7137757 0.77 MME (0.54) MMEACEECE1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP MME 99/4885ACE 44/4885ECE1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.